Clinical Trials at JFK Medical Center
Developing the Future of Medicine
Advances in medicine come from new ideas developed through clinical research.
At JFK Medical Center, we conduct clinical trials (also called research trials or research studies) in our ongoing effort to discover and deliver more effective treatment. Our goal is to translate discoveries made in the laboratory to the patients who will benefit from them, as quickly as possible.
In order to participate in a clinical trial, certain eligibility requirements need to be met. You can discuss the criteria with the clinical trials team.
Please review our current available clinical trials below, and call or e-mail the contact person(s) listed for a trial to get a more thorough explanation of that study.
JFK Neuroscience Institute Clinical Trials
JFK Brain Tumor Center
Stroke
Huntington’s Disease
Seizure Trials Ophthalmology TrialFor these trials, please contact Charles Porbeni, Clinical Trails Coordinator at 732-321-7000, ext. 68897
Oncology Clinical Trials
For these trials, please contact Linda Thomas, Clinical Trial Coordinator at 732-321-7000, ext. 61689
JFK Health System Oncology Clinical Trials
October 2011
Brain Tumor Trials
ICT -107 A Randomized, Double-Blind, Controlled Phase II Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients with Stage IV Glioblastoma Multiforme (GBM) Following Resection and ChemoradiationThe study includes standard of care treatment with radiation and temozolomide followed by 4 weekly injections of study drug (vaccine or placebo) and subsequent maintenance of temozolomide for 12 cycles with selected months for additional study drug.
Celldex An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant
ACT IV Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
CDX-10-04
In this study, after standard of care radiation and temozolomide, the subject will be randomized to receive study vaccine, either rindopepimut/GM-CSF or control drug (KLH) in combination with standard maintenance temozolomide for six to twelve cycles.
Tocagen A Phase I Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector
Toca 511 Administered to Subjects at the time of Resection for Recurrent High Grade Glioma and Followed by Treatment with Toca FC, Extended-Release 5FC
This is an open label study, ascending-dose trial of the safety and tolerability of increasing doses of Toca 511 administered to the resection cavity of subjects with recurrent or progressive High Grade Glioma. Approximately 7 weeks after surgery, the subjects will take oral 5-FC for 8 days every 8 weeks.
Novocure A Prospective Multi Center Trial of Novo TTF-100A Together with Temozolomide compared to
Novo-TTF Temozolomide alone in Patients with Newly Diagnosed GBM
EF -14
The Novo-TTF is an investigational, non-invasive device that may disrupt the rapid cell division exhibited by cancer cells. Electrodes are applied to the surface of the scalp and deliver alternating electrical waves targeted to the tumor cells, not healthy brain cells. Once applied, the electrode device is carried in a shoulder bag and the subject may continue with their daily routine.
JFK Health System Oncology Clinical Trials
October 2011
NSABP B-39/ A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast
RTOG 0413 Irradiation (PBI) for Women with Stage 0, 1, or II Breast Cancer
In this study, the subject is randomized to either whole breast radiation which is once a day, 5 days a week for 5-7 weeks, or partial breast radiation which is given 2 times a day, 6 hours apart on 5 days (over a 5-10 day period).
ACOSOG Phase III Prospective Randomized Trial Comparing Laparoscopic Assisted Resection versus Open
Z6051 Resection for Rectal Cancer
In this study, subjects receive standard of care chemotherapy prior to surgery. Subjects are randomized to an open surgical procedure to remove the rectal tumor, or to a laparoscopic surgical procedure to remove the tumor. Chemotherapy is resumed after the surgery.
CINJ Health Behaviors among Individuals Diagnosed with Colorectal Cancer
130901
Subjects who have completed chemotherapy for colon or rectal cancer are asked to participate in a questionnaire survey on diet and physical activity.
Stroke Clinical trials
A randomized, double-blind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke (DIAS- 4) USA.
The primary objective of the study is to evaluate the efficacy of a new clot-buster (desmoteplase) versus placebo in terms of favorable outcome in subjects with acute ischemic stroke. This drug can be given up to 9 hours after a stroke compared to the currently approved drug which must be given within 3.5 hours of a stroke.
Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III
The aim of this study in patients with hemorrhagic stroke is to determine whether extraventricular drain (EVD) placement with low-dose rt-PA improves clinical outcome compared to subjects treated with EVD placement with placebo.
A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage
The study is to determine the benefit of intensive SBP treatment (SBP<140 mmHg) compared with standard SBP treatment (SBP<180 mmHg) in reducing the proportion of patients with death and disability among subjects with ICH treated within 3.5 hours of symptom onset.
A Multicenter Observational Study to Evaluate the Simplified‑STroke REhabilitation Assessment of Movement (S‑STREAM) Scale in Subjects Obtained Between 24 and 48 Hours of a Nonhemorrhagic Ischemic Stroke
The study’s objective is to assess the validity of a rating scale used in assessing voluntary motor ability in patients with acute ischemic stroke.
Huntington’s Trials
Coenzyme Q10 (Co Q) in Huntington’s disease
The study objective is to investigate the efficacy and long-term safety of chronic Coenzyme Q10 (CoQ) treatment in slowing functional decline in early Huntington’s disease subjects, and also to examine the long-term safety of CoQ in this population.
Seizure Trials
A Historical-controlled, multicenter, double-blind, randomized trial to assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures
The study aims at converting people on multiple anti epilepsy drugs to one drug (monotherapy)
The idea is that monotherapy is likely to result in a lower incidence of AEs related to Anti Epilepsy Drug therapy (thus improving tolerability); lower medication costs and is likely to result in greater subject compliance
A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset SeizuresA0081194 (Trial of Pregabalin Controlled release formulation as adjunctive therapy in adults with partial onset seizures)
This will be an open label continuation of the SPO2 study
A Randomized, Double-Blinded, Placebo-Controlled, Parallel Group, Multi-Center Trial of Pregabalin controlled release formulation as adjunctive therapy in adults with Partial Onset Seizures
The study is to evaluate the efficacy of two different dosages of Pregabalin CR administered once daily as compared to placebo as adjunctive treatment in reducing the frequency of seizures in partial onset epilepsy.
Ophthalmology Trial
A Prospective study to evaluate the possible association between the use of PDE5 Inhibitors and the risk of acute nonarteritic anterior ischemic optic neuropathy (NAION)
People who have had sudden loss of vision in one eye are asked to participate in a questionnaire study on lifestyle and use of medications like Viagra.
NAION ( Non Arteritic ischemic Optic Neuropathy )
